Metformin has evidence-based and potential uses in treating PCOS-related disturbances, including menstrual disorders, infertility, hyperandrogenism, and metabolic abnormalities.
Does metformin improve clinical, metabolic, and cardiovascular outcomes in women with polycystic ovary syndrome?
Metformin has multiple potential and evidence-based benefits in managing PCOS, extending beyond its insulin-sensitizing effects to address reproductive, metabolic, and cardiovascular abnormalities.
Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus. Because many women with polycystic ovary syndrome (PCOS) are insulin resistant, metformin was introduced in clinical practice to treat these patients also. Moreover, metformin's effect has other targets beside its insulin-sensitizing action. The present review was aimed at describing all evidence-based and potential uses of metformin in PCOS patients. In particular, we will analyze the uses of metformin not only for the treatment of all PCOS-related disturbances such as menstrual disorders, anovulatory infertility, increased abortion, or complicated pregnancy risk, hyperandrogenism, endometrial, metabolic and cardiovascular abnormalities, but also for the prevention of the syndrome.
Palomba et al. (Thu,) conducted a review in Polycystic Ovary Syndrome (PCOS). Metformin was evaluated. Metformin has evidence-based and potential uses in treating PCOS-related disturbances, including menstrual disorders, infertility, hyperandrogenism, and metabolic abnormalities.